ERAS Stock Analysis: Buy, Sell, or Hold?
ERAS - Erasca, Inc. Common Stock
$17.63
0.55 (3.22%)
▲
5d:
-4.08%
30d:
-8.84%
90d:
+51.92%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 21, 2026 at $17.63 · last confirmed Aug 21, 2026
Strength: 6.2/10
Get Alerted When ERAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ERAS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ERAS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ERAS is currently trading at $17.63, which is considered oversold relative to its 30-day fair value range of $17.78 to $19.32.
Technical Outlook: Technically, ERAS is in a uptrend. Immediate support is located at $16.92, while resistance sits at $19.22. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $23.50 (+33.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ERAS is in a uptrend. Immediate support is located at $16.92, while resistance sits at $19.22. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $23.50 (+33.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$17.78 -
$19.32
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
Protect Your Profits
Holding ERAS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 33.3% below Wall St target ($23.50)
- NEUTRAL: Bottoming setup forming (53/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$17.78 -
$19.32
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$16.92
Resistance Level
$19.22
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.52
Wall Street Target
$23.50
(+33.3%)
Share & Embed Analysis
Last updated: August 23, 2026 1:00 AM ET
Data refreshes hourly during market hours. Next update: 2:00 AM
Data refreshes hourly during market hours. Next update: 2:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ebun Garner
SELL
80000 shares
2026-04-01
Shannon Morris
SELL
20000 shares
2026-03-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
Advanced ERAS Option Strategies
Professional options setups generated by AI based on today's ERAS price and gamma walls.
